TABLE 1.
Characteristics of women in the discovery and replication stages.
| Discovery Stage |
Replication Stage |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PMH- CCFR |
WHI1 | WHI2 | NHS | VITAL | Combined Replication |
|||||||
| No. of women with CRC | 729 | 430 | 910 | 260 | 129 | 1,729 | ||||||
| No. of deaths | 244 | 157 | 257 | 104 | 37 | 555 | ||||||
| No. of deaths from CRC | 161 | 113 | 192 | 77 | 23 | 405 | ||||||
| Age at diagnosis (years), N (%) | ||||||||||||
| Range | 50–74 | 52–86 | 50–91 | 52–85 | 55–83 | 50–91 | ||||||
| Mean (SD) | 63.9 | (7.2) | 70.9 | (7.0) | 71.9 | (7.2) | 68.5 | (7.3) | 70.7 | (6.1) | 71.1 | (7.2) |
| 50–59 | 220 | (30) | 25 | (6) | 33 | (4) | 28 | (11) | 9 | (7) | 95 | (5) |
| 60–69 | 302 | (41) | 141 | (33) | 309 | (34) | 118 | (45) | 41 | (32) | 609 | (35) |
| ≥ 70 | 207 | (28) | 264 | (62) | 568 | (62) | 114 | (44) | 79 | (61) | 1,025 | (59) |
| Caucasian race, N (%) | 674 | (92) | 430 | (100) | 910 | (100) | 260 | (100) | 129 | (100) | 1,729 | (100) |
| Postmenopausal hormone therapya, N (%) | ||||||||||||
| No | 309 | (44) | -- | -- | 328 | (56) | 122 | (52) | 62 | (53) | 512 | (54) |
| Yes | 401 | (56) | -- | -- | 261 | (44) | 114 | (48) | 56 | (47) | 431 | (46) |
| Not available | 19 | -- | -- | -- | 321 | -- | 24 | -- | 11 | -- | 356 | -- |
| Tumor subsite, N (%) | ||||||||||||
| Proximal colon | 352 | (48) | 283 | (66) | 462 | (51) | 132 | (51) | 71 | (56) | 948 | (55) |
| Distal colon | 251 | (34) | 135 | (32) | 216 | (24) | 72 | (28) | 31 | (25) | 454 | (27) |
| Rectum | 126 | (17) | 9 | (2) | 227 | (25) | 54 | (21) | 24 | (19) | 314 | (18) |
| Not available | 0 | -- | 3 | -- | 5 | -- | 2 | -- | 3 | -- | 13 | -- |
| Stage at diagnosis, N (%) | ||||||||||||
| Localized | 309 | (42) | 172 | (40) | 392 | (43) | 60 | (23) | 58 | (45) | 682 | (39) |
| Regional | 344 | (47) | 196 | (46) | 397 | (44) | 150 | (58) | 48 | (37) | 791 | (46) |
| Distant | 76 | (10) | 62 | (14) | 121 | (13) | 50 | (19) | 23 | (18) | 256 | (15) |
| 5-year CRC-specific Survival, % (95% CI) | 78 (74, 81) | 73 (68, 77) | 76 (72, 79) | 72 (66, 77) | 80 (71, 87) | 75 (72, 77) | ||||||
| 5-year Overall Survival, % (95% CI) | 75 (71, 78) | 67 (62, 71) | 70 (66, 73) | 70 (64, 76) | 73 (63, 80) | 69 (67, 72) | ||||||
a
Prediagnostic use of estrogen-alone or estrogen+progestin. Use one year prior to diagnosis for PMH-CCFR, at baseline questionnaire for WHI2 and VITAL, in 1990 for NHS. Not available for WHI-OS.
Abbreviations: CI, confidence interval; CRC, colorectal cancer; PMH-CCFR, Postmenopausal Hormones Supplementary Study to the Colon Cancer Family Registry; NHS, Nurses’ Health Study; OS observational study; SD, standard deviation; VITAL, VITamins And Lifestyle Study; WHI1, Women’s Health Initiative WHI2, Women’s Health Initiative Set 2.